Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

press release, particularly those anticipating future clinical trials and business prospects for Zerenex(TM) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for Zerenex(TM); the risk that the data (both safety and efficacy) from the Phase 3 trials will not coincide with the data analyses from the Phase 2 clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the FDA website is not incorporated by reference into this press release and is included for reference purposes only. KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)... 2014  Northstar Global Business Services, Inc. (OTCPink:MDIN) ... has made their final decision and has determined ... stock effective December 15, 2014, and has resumed ... and book entry transfer services. All deposit restrictions have ... again fully "DTC Eligible", and has resumed electronic ...
Breaking Medicine Technology:Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3
... Target Patients for ALIMTA(R), (pemetrexed for injection) ... Cancer, BARCELONA, Spain, Sept. 25 ... lung cancer (NSCLC) that,are classified as having ... when treated in the second-line setting with,ALIMTA(R) ...
... Mich. Sept. 24 Velcura Therapeutics, Inc., a,biotechnology ... the,U.S. Food and Drug Administration (FDA) Sept. 20 ... VEL-0230, a drug developed to treat bone,disease. The ... was to obtain feedback from the FDA,s Division ...
Cached Medicine Technology:Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 2Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 3Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 4Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 5Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 6Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 7Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 8Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 2Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease 3
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... moms who were exposed to high levels of air pollution ... autism, a U.S. study suggests. Researchers found that of ... 2002, those exposed to the most air pollution during pregnancy ... developed autism. And exposure during the third trimester, specifically, showed ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a new ... and co-founder of the Ace Medical Weight Loss Center in ... broad look at the industry of weight loss, and how ... film and in television shows, however, she says the topic ... and played for basic laughs, which she believes impacts whether ...
(Date:12/17/2014)... HeartMath® Inc., recognized as one of the ... (HRV), heart coherence and the physiology of emotions, ... algorithms to chipset manufacturers and consumer electronics companies. ... offer its HRV solutions, tap into its HRV ... normative HRV databases and algorithms for developing consumer ...
(Date:12/17/2014)... No matter how far modern medicine advances, ... head louse parasite—a common childhood malady and a source ... six and twelve million individuals will suffer an infestation. ... company comes to the rescue, providing an all-natural treatment ... track record of customer service, and effectiveness in getting ...
Breaking Medicine News(10 mins):Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... key part of health care reform that requires all Americans ... people gaining coverage, but would not dramatically increase the cost ... comes as the U.S. Supreme Court prepares to hear arguments ... key provision of 2010,s Affordable Care Act. According ...
... News) -- Using an autoinjector device to deliver ... effective way to treat status epilepticus, a prolonged type ... report. "This is a very important study for ... French, first vice president of the American Epilepsy Society. ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- How fast you ... help predict your odds for dementia or stroke later in life, ... can be easily performed in a doctor,s office, noted study author ... and her colleagues tested the walking speed, hand grip strength and ...
... Hospitalization for underage drinking is common in the United States, ... total cost for these hospitalizations is about $755 million per ... found geographic and demographic differences in the incidence of alcohol-related ... Journal of Adolescent Health . Of the ...
... may be receiving the highest exposure to nanoparticles of titanium ... than adults, according to a new study. Published in ACS, ... first broadly based information on amounts of the nanomaterial ... and environmental effects in a wide range of consumer ...
... -- About 27 million Americans aged 50 and older have ... hearing aid, a new study finds. However, many people ... insurance, they don,t receive training in integrating hearing aids into ... part of aging and not a major concern, according to ...
Cached Medicine News:Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 2Health News:Ending individual mandate would not dramatically hike insurance prices, study finds 3Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 2Health News:'Autoinjector' Offers Safe, Speedy Care for Life-Threatening Seizures: Study 3Health News:Can Walking Speed, Hand Grip in Middle Age Predict Dementia Risk? 2Health News:Mayo Clinic: Hospitalization of US underage drinkers common, costs $755 million a year 2Health News:Millions of Americans Have Untreated Hearing Loss: Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: